Últimas noticias sobre Ocugen (NASDAQ:OCGN) Bolsa

OCUGEN INC

Ocugen

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Ocugen Inc

Hit rapper Eminem is coming to the big screen again thanks to a partnership with AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>). Will the movie theater chain have <a href="https://www.benzinga.com/general/entertainment/24/03/37701205/taylor-swift-concert-film-hits-streaming-heres-how-to-watch-the-eras-tour-taylors-version">the same success</a> it had with Taylor Swift?
What Happened: Eminem raps that you might have only one shot or one opportunity "to seize everything you ever wanted" in the Academy Award winning song "Lose Yourself." Lucky for AMC, they might have another shot at box office success thanks to <a href="https://www.benzinga.com/general/entertainment/24/05/39010959/amc-ceo-says-were-still-here-how-taylor-swift-popcorn-buckets-help-movie-theater-from-going">an exclusive deal </a>with the musician.
AMC announced it is exclusively releasing "Stans," a documentary from Eminem about fandom in theaters Aug. 7-10.
"This one's for the Stans, by the Stans! See the real stories behind the fandom," AMC <a href="https://x.com/AMCTheatres/status/1945111628325728555">tweeted</a>.
Eminem also <a href="https://x.com/Eminem/status/1945220683841098153">shared </a>the trailer for the movie and also posted to his 21.7 million X followers that you can preorder a "Stans" movie soundtrack vinyl and movie ticket. The vinyl and movie ticket showed a cost of $63. Movie tickets for a theater near this author were listed at $18 each, but may vary by location.
"Released in 2000, Eminem's song ‘Stan' — about an obsessive, unstable fan — remains iconic. So iconic that the term stan was officially added to the Oxford English Dictionary in 2017," the movie's <a href="https://www.amctheatres.com/movies/stans-80811?utm_medium=socialmediapost&amp;utm_source=organicsocial&amp;utm_campaign=80811-stans&amp;utm_content=flm-tos&amp;utm_launch=2025-07-15&amp;sf227562018=1">website </a>reads.
The film will explore fandom and "complicated relationship" between Eminem being a mostly private artist and his "massive public persona." The film will include archival footage, interviews, recreations and an exclusive original interview with Eminem.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/04/38472158/exclusive-eminems-manager-paul-rosenberg-shares-his-story-with-multiplatinum-rapper-nobody-">EXCLUSIVE: Eminem&#8217;s Manager Paul Rosenberg Shares His Story With Multiplatinum Rapper — &#8216;Nobody Wanted To Sign Him, I Didn&#8217;t Give Up&#8217;</a>
Why It's Important: The new "Stans" film will be released by AMC Theatres Distribution, the unit of the movie theater chain that also released concert documentaries from Taylor Swift and Beyoncé.
"Stans" will be shown twice daily in more than 135 AMC locations according to a report from <a href="https://variety.com/2025/film/news/eminem-documentary-stans-amc-theaters-release-1236460929/">Variety</a>. The film will be released for a full week in the AMC Empire 25 in New York to qualify for award nominations.
The film will also get an international release with Trafalgar Releasing launching the film on Aug. 7 in around 1,600 movie theaters in 50 countries expected to show the film.
"Taylor Swift: The Eras Tour" broke records for concert films and <a href="https://www.boxofficemojo.com/title/tt28814949/?ref_=bo_se_r_1">grossed </a>$180.8 million in domestic theaters and $261.7 million worldwide.
The Beyoncé film "Renaissance: A Film By Beyoncé" <a href="https://www.boxofficemojo.com/title/tt29354040/?ref_=bo_se_r_1">grossed </a>$33.9 million domestically and $44.0 million worldwide.
Eminem previously starred as himself in the semi-autobiographical 2002 film "8 Mile." That film <a href="https://www.boxofficemojo.com/title/tt0298203/?ref_=bo_se_r_1">grossed </a>$116.8 million domestically and $242.9 million worldwide.
While there is no guarantee that "Stans" will be a hit, AMC landed exclusive coverage of the movie, which could bring fans to its theaters for the first time to experience premium screens, enhanced food options and win them over as future movie customers.
AMC could also get a piece of future revenue from streaming partnerships and other deals as one of the distribution partners, as it did with the Taylor Swift film.
AMC Price Action: AMC stock closed Wednesday up 1.76% to $3.18 versus a 52-week trading range of $2.45 to $5.76. AMC stock is down 20.9% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46299629/amc-declares-war-on-empty-seats-with-50-midweek-discounts-genius-or-desperation">AMC Declares War On Empty Seats With 50% Midweek Discounts—Genius Or Desperation?</a></li>
</ul>
Photo: Jgphotographydetroit via Shutterstock

Entertainment

Trading Ideas

General

Could Eminem Be AMC's Next Secret Weapon After Taylor Swift Success?

Earnings

Earnings Beats

News

GSBC

Great Southern Bancorp Q2 EPS $1.72 Beats $1.33 Estimate, Sales $50.963M Beat $49.144M Estimate

In the latest quarter, 4 analysts provided ratings for StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.38, a high estimate of $18.50, and a low estimate of $13.00. This current average reflects an increase of 24.23% from the previous average price target of $12.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1752703269_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of StoneCo among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yuri Fernandes</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.50</td>
<td>$15.50</td>
</tr>
<tr>
<td>John Coffey</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>John Coffey</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Gustavo Schroden</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to StoneCo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of StoneCo compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for StoneCo's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into StoneCo's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/STNE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on StoneCo analyst ratings.</a>
<h2>Get to Know StoneCo Better</h2>
StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.
<h3>StoneCo's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: StoneCo displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 18.08%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): StoneCo's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.44%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): StoneCo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: StoneCo's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.18.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

STNE

Analyst Expectations For StoneCo's Future

In the last three months, 7 analysts have published ratings on Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Aeva Technologies and provided 12-month price targets. The average target is $19.14, accompanied by a high estimate of $33.00 and a low estimate of $9.00. Marking an increase of 89.5%, the current average surpasses the previous average price target of $10.10. 
<img src="https://www.benzinga.com/files/images/story/2025/1752703255_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Aeva Technologies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Suji Desilva</td>
<td>Roth Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Suji Desilva</td>
<td>Roth Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$5.22</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Aeva Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aeva Technologies compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Aeva Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Aeva Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AEVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Aeva Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Aeva Technologies's Background</h2>
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
<h3>A Deep Dive into Aeva Technologies's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Aeva Technologies's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 59.85%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Aeva Technologies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1035.24%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Aeva Technologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -41.47%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Aeva Technologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -26.61%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEVA

What Analysts Are Saying About Aeva Technologies Stock

Across the recent three months, 35 analysts have shared their insights on UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">24</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">18</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for UnitedHealth Group, presenting an average target of $425.03, a high estimate of $600.00, and a low estimate of $270.00. This current average has decreased by 21.52% from the previous average price target of $541.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1752703248_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive UnitedHealth Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$345.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$337.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$385.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$418.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$312.00</td>
<td>$356.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$353.00</td>
<td>$552.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Sidharth Sahoo</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$270.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Justin Lake</td>
<td>Wolfe Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$501.00</td>
</tr>
<tr>
<td>Ryan Langston</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$308.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$360.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$362.00</td>
<td>$513.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$362.00</td>
<td>$521.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$351.00</td>
<td>$677.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$374.00</td>
<td>$563.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$356.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$552.00</td>
<td>$552.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$510.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$513.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$525.00</td>
<td>$652.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$525.00</td>
<td>$655.00</td>
</tr>
<tr>
<td>Sidharth Sahoo</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Hold</td>
<td>$490.00</td>
<td>$595.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$563.00</td>
<td>$664.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$580.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$560.00</td>
<td>$642.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$575.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$540.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$600.00</td>
<td>$640.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of UnitedHealth Group compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of UnitedHealth Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UnitedHealth Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UNH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on UnitedHealth Group analyst ratings.</a>
<h2>Discovering UnitedHealth Group: A Closer Look</h2>
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>UnitedHealth Group: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: UnitedHealth Group displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.8%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: UnitedHealth Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): UnitedHealth Group's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): UnitedHealth Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.07% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: UnitedHealth Group's debt-to-equity ratio is below the industry average at 0.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For UnitedHealth Group's Future

Throughout the last three months, 11 analysts have evaluated Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $98.82, a high estimate of $114.00, and a low estimate of $88.00. Marking an increase of 0.73%, the current average surpasses the previous average price target of $98.10. 
<img src="https://www.benzinga.com/files/images/story/2025/1752703238_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Consolidated Edison's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Anthony Crowdell</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$107.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$92.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$93.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Anthony Crowdell</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Sophie Karp</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$101.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Sarah Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$114.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Shahriar Pourreza</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$103.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$94.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Consolidated Edison. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Consolidated Edison compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Consolidated Edison's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Consolidated Edison's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ED/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Consolidated Edison analyst ratings.</a>
<h2>Unveiling the Story Behind Consolidated Edison</h2>
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange &amp; Rockland, or O&amp;R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York - including New York City and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
<h3>Consolidated Edison's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Consolidated Edison showcased positive performance, achieving a revenue growth rate of 12.1% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Utilities sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Consolidated Edison's net margin excels beyond industry benchmarks, reaching 16.49%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Consolidated Edison's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.46% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Consolidated Edison's ROA excels beyond industry benchmarks, reaching 1.12%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.1.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Consolidated Edison Stock: Analyst Perspectives (11 Ratings)

In the last three months, 38 analysts have published ratings on Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">15</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">7</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $329.37, a high estimate of $430.00, and a low estimate of $200.00. This current average represents a 5.35% decrease from the previous average price target of $347.97. 
<img src="https://www.benzinga.com/files/images/story/2025/1752703231_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Salesforce is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$430.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$275.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$430.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$335.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Matthew Vanvliet</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Matthew Vanvliet</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$370.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Matthew Vanvliet</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$325.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$295.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Brett Huff</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$309.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$335.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$370.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$396.00</td>
<td>$423.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$404.00</td>
<td>$393.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$347.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Underperform</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Mark Moerdler</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Underperform</td>
<td>$255.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$275.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Maintains</td>
<td>Buy</td>
<td>$340.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$367.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Adjusts</td>
<td>Buy</td>
<td>$340.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$255.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Underperform</td>
<td>$200.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Salesforce. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Salesforce compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Salesforce's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Salesforce's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CRM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Salesforce analyst ratings.</a>
<h2>About Salesforce</h2>
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
<h3>Key Indicators: Salesforce's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Salesforce showcased positive performance, achieving a revenue growth rate of 7.62% as of 30 April, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Salesforce's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Salesforce's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.53%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.53%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Salesforce's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 38 Analyst Ratings Have To Say About Salesforce

In the current market session, First American Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FAF#NYSE">FAF</a>) price is at $55.45, after a 1.32% increase. However, over the past month, the stock fell by 4.03%, and in the past year, by 3.78%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1752703225_0.png" alt="Past Year Chart" />

<h3>How Does First American Financial P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 22.18 in the Insurance industry, First American Financial Inc. has a higher P/E ratio of 36.01. Shareholders might be inclined to think that First American Financial Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752703225_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for First American Financial

14 analysts have expressed a variety of opinions on Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $24.43, with a high estimate of $30.00 and a low estimate of $18.00. A 10.77% drop is evident in the current average compared to the previous average price target of $27.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1752703222_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Norwegian Cruise Line by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Robin Farley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Norwegian Cruise Line. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Norwegian Cruise Line compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Norwegian Cruise Line's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Norwegian Cruise Line's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NCLH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Norwegian Cruise Line analyst ratings.</a>
<h2>All You Need to Know About Norwegian Cruise Line</h2>
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 70,000). It operates 33 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 12 passenger vessels on order among its brands through 2036, representing 37,500 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
<h3>Norwegian Cruise Line's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Norwegian Cruise Line's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.91% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Norwegian Cruise Line's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.84%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Norwegian Cruise Line's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.19%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Norwegian Cruise Line's debt-to-equity ratio is notably higher than the industry average. With a ratio of 9.88, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NCLH

What Analysts Are Saying About Norwegian Cruise Line Stock

LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) has outperformed the market over the past 10 years by 11.6% on an annualized basis producing an average annual return of 23.02%. Currently, LPL Finl Hldgs has a market capitalization of $29.46 billion. 
Buying $1000 In LPLA: If an investor had bought $1000 of LPLA stock 10 years ago, it would be worth $7,776.82 today based on a price of $368.31 for LPLA at the time of writing.
<h3>LPL Finl Hldgs's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752703212_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LPLA

Here's How Much You Would Have Made Owning LPL Finl Hldgs Stock In The Last 10 Years

Offerings

GAME

GameSquare Holdings Announces Proposed Public Offering of Common Stock; Size Not Disclosed

Harleysville Finl (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HARL#OTC">HARL</a>) reported quarterly earnings of $0.70 per share. This is a 16.67 percent increase over earnings of $0.60 per share from the same period last year. The company reported $7.001 million in sales this quarter. This is a 11.23 percent increase over sales of $6.294 million the same period last year.

HARL

Harleysville Finl Q3 EPS $0.70 Up From $0.60 YoY, Sales $7.001M Up From $6.294M YoY

Reuters Cites Coca-Cola Spokesperson Saying Appreciate President Trump's Enthusiasm For Our Brand; More Details On New Innovative Offerings Within Our Coca-Cola Product Range Will Be Shared Soon

Motorola Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) has outperformed the market over the past 20 years by 28.52% on an annualized basis producing an average annual return of 36.98%. Currently, Motorola Solutions has a market capitalization of $69.51 billion. 
Buying $100 In MSI: If an investor had bought $100 of MSI stock 20 years ago, it would be worth $52,036.25 today based on a price of $416.29 for MSI at the time of writing.
<h3>Motorola Solutions's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752702311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Motorola Solutions 20 Years Ago Would Be Worth Today

<a href="https://www.bloomberg.com/news/articles/2025-07-16/tesla-failed-to-stop-autopilot-misuse-safety-expert-testifies">https://www.bloomberg.com/news/articles/2025-07-16/tesla-failed-to-stop-autopilot-misuse-safety-expert-testifies</a>

TSLA

'Tesla Failed to Stop Autopilot Misuse, Safety Expert Testifies'- Bloomberg

Biotech

FBIO

Fortress Biotech Reveals AstraZeneca's Anselamimab Trial Did Not Achieve Statistical Significance

Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) has outperformed the market over the past 20 years by 1.69% on an annualized basis producing an average annual return of 10.15%. Currently, Watts Water Technologies has a market capitalization of $8.24 billion. 
Buying $1000 In WTS: If an investor had bought $1000 of WTS stock 20 years ago, it would be worth $6,950.48 today based on a price of $247.02 for WTS at the time of writing.
<h3>Watts Water Technologies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752701420_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Watts Water Technologies 20 Years Ago Would Be Worth This Much Today

MOCKSVILLE, N.C., July 16, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction is creating a new pathway to reducing the rate of smoking and related health harms through increasing adoption of its VLN&#xAE; reduced nicotine content cigarette products by additional brands. Our products incorporate proprietary and patented tobacco having 95% less nicotine than tobacco used in highly addictive conventional cigarettes. Decades of peer reviewed studies have shown that the level of nicotine content in 22nd Century's products can reduce both the rate of smoking and the health harms of smoking.
The recently announced partner VLN&#xAE; initiatives, such as Smoker Friendly VLN&#xAE;, Pinnacle VLN&#xAE;, reflect a growing commitment by tobacco brands to accelerate compliance with the U.S. Food and Drug Administration's proposed new <a href="https://www.globenewswire.com/Tracker?data=qlpGKAiiF5amDEZPNG9E1wa0Bx3dDtMM77VR4RbGJWSubkI9NnsX4N1cBnG6QdN_kUoNErrTFIBV7KXnUVtrBN6QnbLszIYZiP-IXRrNi4aZKKYUOwJXlHz20F14ZOUA4rq83ew202ivfMaQwgyfnbs7rflxFw73cB7OOmHanCVTsyNlxkQqi2Ay00DeHYTTwyYQ_Kj6P81tDgEi18eBilqqsUy3Cp81M4rSMJ4ZhIe5XYRnoe5ltraZ32_Hih3F">Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products</a>, which is intended to curb the harms of smoking.
"The FDA recognizes that nicotine is a highly addictive substance and that to achieve true tobacco harm reduction, nicotine consumption must be addressed. The FDA's new product standard proposed in January is one of many factors that are driving early commercial interest in our VLN reduced nicotine content tobacco products. We are excited to see our customer's brands adding VLN cigarettes to their lineup. This will enhance market availability of VLN cigarettes and offer customers a Tobacco Harm Reduction product that will give the smoker a choice to control their nicotine consumption," said Larry Firestone, Chief Executive Officer of 22nd Century Group. "These commercial launches and our readiness once we receive state approval to scale availability to all 50 states for the entire U.S. cigarette market continues to demonstrate that there need not be any commercial barriers to adopting this FDA policy, which could be the most impactful health decision in a generation."
Formally announced in January 2025, the proposed standard sets a maximum nicotine content of 0.7 mg of nicotine per gram of tobacco in cigarettes and certain other combusted tobacco products, taking effect two years from final approval. VLN&#xAE; based products from 22nd Century are the only combustible cigarette products authorized by the FDA to meet the standard, at an average of 0.5 mg per gram, and the only product that offers consumers a choice about their nicotine consumption.
On implementation of the FDA proposal, people who are addicted and wish to alter their dependency or even quit could have the ability to do so more easily, significantly reducing the morbidity and mortality caused by smoking. Based on FDA's population health model, by the year 2100, in the United States, approximately 48 million youth and young adults who would have otherwise initiated smoking would not start as a result of the proposed product standard.
22nd Century is monitoring comment submissions under the proposed rule and intends to make its own submission before the comment period closes.
This activity follows the 2018 rule making process, which ultimately incorporated many of the suggestions, independent clinical research studies and feasibility data from <a href="https://www.globenewswire.com/Tracker?data=hu5Ct19R2VxJK1gnvpGqpKi-1bjPVXLyYhiKAu_4DsP23n5DivM-Nbokt2G7wUqlRbM_EMgpddvZzLc2hVHmW655I4SF60Dlx5HKIPOR1MbBGl_BScadSFdFodZvABp9a5M3NwrNt2ZavMxeO6mawHW470JYY6bHFG3mGw3gBng=">22nd Century's comment letter at that time</a>, including:
<ul>
<li>A proposed standard of not more than 0.7mg/g of nicotine content, based on 22nd Century's recommendation of an average of 0.5mg/g,</li>
<li>The fact that our patented low nicotine content tobacco leaf contained in our VLN Products that already meets the standard can be readily sourced in enough quantity to meet demand for reduced nicotine content cigarette products, and</li>
<li>The fact the reduced nicotine content tobacco is an effective way to reduce the rate and harms of smoking, as documented by dozens of peer reviewed and published independent clinical studies using research cigarettes manufactured by 22nd Century &nbsp;</li>
</ul>
The <a href="https://www.globenewswire.com/Tracker?data=0Muji-qgH5MFNwCDVb86z3wLdp65rxkCvpIGpTpnNfIiwEfFZI8YdRDGe7JKTN_y7BNIAxpGiFJ_3i3Ovfxx35ZmAI1S_-iP-PMpFJVadmBBI5WcCjn4VWoTfpc1k3OK9MuYQNy9mpUOh-gLikypMsac4w8-ysu5Wu_FPebSjUml0znYBoH97FfzgN_mFcB8bqx1EZCXj3eXmfSywdZGvSk-bPPambpvRbGxO-FCE5LN-eQNXrjXDuTyShONIyHszhjR_aBNGKe8FHA8K8JkEca8MWYfhFeU6yL6WB5F1lvtZBOJ33ii_DAcZpVRau6QxS8hTxm_9lGGGk8cFHhwJT9WorjZ3UFxTNPROdVbZ-czEclwanfiP7Tjdih9VtWyP1gFni13VIaofKXo-Qmk1w==">FDA's January 15, 2025 press release</a> announcing the rule includes the following statement from the former FDA Commissioner Robert M. Califf, M.D.: "Today's proposal envisions a future where it would be less likely for young people to use cigarettes and more individuals who currently smoke could quit or switch to less harmful products. This action, if finalized, could save many lives and dramatically reduce the burden of severe illness and disability, while also saving huge amounts of money. I hope we can all agree that significantly reducing the leading cause of preventable death and disease in the U.S. is an admirable goal we should all work toward."

XXII

22nd Century Group Reveals Multiple Tobacco Brands Partnering With 22nd Century To Expand Availability and Awareness of VLN-Based Reduced Nicotine Content Products

Union Bankshares Q2 EPS $0.53 Up From $0.45 YoY, Sales $13.200M Up From $12.300M YoY

HOMB

Home BancShares Q2 Adj. EPS $0.58 Beats $0.57 Estimate, Sales $271.000M Beat $262.560M Estimate

Health Care

Press Releases

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Comments

Ocugen

Noticias

Últimas noticias sobre Ocugen (NASDAQ:OCGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL